SCHEMBL925205

SCHEMBL925205

Nc1ccc(Nc2ncnc3sc4c(c23)CCCC4)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 6/20 0.79
FGFR1 P11362 2/20 0.79
MAPT P10636 6/20 0.76
MAPK1 P28482 3/20 0.74
MEN1 O00255 1/20 0.74
POLB P06746 1/20 0.74
HPGD P15428 1/20 0.74
KMT2A Q03164 1/20 0.74
TP53 P04637 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
RAF1 P04049 2/20 0.73
HTT P42858 2/20 0.73
GAA P10253 2/20 0.73
KDM4E B2RXH2 2/20 0.73
ALDH1A1 P00352 2/20 0.73
GLA P06280 1/20 0.73
LMNA P02545 1/20 0.69
EGFR P00533 3/20 0.67
MAP2K1 Q02750 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL923228 0.88 MKNK1 (1.00) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL923658 0.88 FGFR1 (1.00) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL4039669 0.88 MAPK1 (0.95) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL924123 0.85 MKNK1 (0.77) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL759362 0.82 LMNA (0.63) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL12375203 0.80 MAPT (0.94) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL922549 0.79 EGFR (1.00) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL923247 0.79 MKNK1 (1.00) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL4045792 0.79 MKNK1 (0.76) MKNK1FGFR1MAPTMAPK1MEN1
SCHEMBL29881929 0.77 MAPT (1.00) MKNK1FGFR1MAPTMAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8802849-B2 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use VICHEM CHEMIE KUTATÓ KFT. (HU) 2014-08-12 US claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US claimed
EP-2257554-A1 TRICYCLIC BENZOÝ4,5¨THIENO-Ý2,3-D¨PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE Vichem Chemie Kutató KFT (HU) 2010-12-08 EP claimed
WO-2009104026-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATÓ KFT (HU) 2009-08-27 WO claimed
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE VICHEM CHEMIE KUTATO KFT. (HU) 2011-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015214-A1 TRICYCLIC BENZO[4,5]THIENO-[2,3-D]PYRIMIDINE-4-YL-AMIN DERIVATIVES, THEIR SALTS, PROCESS FOR PRODUCING THE COMPOUNDS AND THEIR PHARMACEUTICAL USE TYMS, TYMP, DPYD MKNK1 2917/4885FGFR1 1511/4885MAPT 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.